IDEAYA and Servier Report Breakthrough mUM Phase 3 Data
SOUTH SAN FRANCISCO, Calif., June 1, 2026 IDEAYA Biosciences and Servier have unveiled compelling results from the registrational Phase...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
SOUTH SAN FRANCISCO, Calif., June 1, 2026 IDEAYA Biosciences and Servier have unveiled compelling results from the registrational Phase...
THOUSAND OAKS, Calif., June 1, 2026 Amgen has secured a major regulatory milestone with the European Commission approval of...
MOUNTAIN VIEW, Calif., May 29, 2026 NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of...
